## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.24 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($447.89)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Jim Cramer on HCA Healthcare: “I Think It’s a Terrific One to Buy”**
- Source: Insider Monkey | 20251221T101400 | Bullish | Relevance: 100%
- Jim Cramer recommends HCA Healthcare due to its significant share buyback activity and consistent performance, despite a recent pullback. L1 Capital, while still invested, has trimmed its HCA holdings, noting increased share price and a less favorable risk-adjusted return potential compared to past opportunities. The article also suggests that certain AI stocks might offer higher returns in a shorter timeframe.

**2. Price Over Earnings Overview: HCA Healthcare**
- Source: Benzinga | 20251222T210833 | Neutral | Relevance: 100%
- HCA Healthcare Inc. (NYSE: HCA) shares are currently trading at $472.00, experiencing a slight decrease of 0.21% in the current session. While the stock has decreased by 8.48% over the past month, it has shown strong long-term performance with a 54.99% increase over the past year. The article highlights HCA Healthcare's Price-to-Earnings (P/E) ratio of 18.29, which is higher than the Health Care Providers & Services industry aggregate of 16.69, suggesting investors might expect better future performance or that the stock could be overvalued.

**3. Jim Cramer on HCA Healthcare: “I think it’s a terrific one to buy”**
- Source: MSN | 20251221T150749 | Bullish | Relevance: 100%
- Jim Cramer of CNBC's "Mad Money" recommended HCA Healthcare, stating it's a terrific stock to buy. He highlighted the company's attractive valuation and strong position in the healthcare sector as key reasons for his bullish outlook. Cramer's endorsement signals confidence in HCA Healthcare's future performance.

**4. HCA Healthcare, Inc. $HCA Shares Sold by Wedge Capital Management L L P NC**
- Source: MarketBeat | 20251221T123513 | Bullish | Relevance: 100%
- Wedge Capital Management L L P NC reduced its stake in HCA Healthcare by 16.4%, selling 17,374 shares and now holding 88,410 shares valued at $37.68 million. The company exceeded Q3 expectations with an EPS of $6.96 versus a $5.64 consensus and revenue of $19.16 billion, setting FY2025 guidance at $27.00–$28.00 EPS. Analysts maintain a "Moderate Buy" rating with a $479 target, and HCA declared a quarterly dividend of $0.72 per share.

**5. HCA Healthcare, Inc. $HCA Shares Sold by Voya Investment Management LLC**
- Source: MarketBeat | 20251221T122413 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC reduced its stake in HCA Healthcare (NYSE:HCA) by 9.3% in the third quarter, selling 7,116 shares and valuing its remaining shares at $29.48 million. Other institutional investors adjusted their positions, and insider data shows EVP Michael R. Mcalevey sold 3,892 shares worth over $1.8 million. Analysts currently rate HCA with a "Moderate Buy" consensus and an average target price of $479.00.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.24 suggests fair value with growth premium. Forward P/E 15.9x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.5B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.24 |
| Forward P/E | 15.9 |
| Current P/E | 17.0 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at -3.6% (minimal 5-day change). Below STRENGTH zone by 7.6pp (needs >4.0% for momentum thesis). Underperforming sector by 3.4pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-3.45), momentum weakening. RSI neutral at 46. Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.57% (CS: 15) | Weak |
| RSI_14 | 46.5 | Neutral |
| MACD Histogram | -3.45 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 1.006x | Above |
| vs SMA200 | 1.190x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $472.07
- **Stop Loss:** $447.89 (5.1% risk)
- **Target:** $520.43 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 49
- **Position Value:** $23,131.43
- **Portfolio %:** 23.13%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*